Novavax Inc (NVAX) stock
NVAXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$7.96+0.00 (0.00%)
Close on Nov 18, 2026Market cap $1.31BP/E –Yield –
Novavax revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Novavax's revenue for the twelve months ending Jun 30, 2026 was $413.80M, down 61.6% year over year. For fiscal 2025 it was $1.12B, up 64.7% from the year before. Over ten years it grew 41.0% a year on average. The highest annual figure on record is $1.98B in fiscal 2022.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.12B | +64.7% |
| FY2024 | Dec 31, 2024 | $682.16M | -30.7% |
| FY2023 | Dec 31, 2023 | $983.71M | -50.4% |
| FY2022 | Dec 31, 2022 | $1.98B | +72.9% |
| FY2021 | Dec 31, 2021 | $1.15B | +141.0% |
| FY2020 | Dec 31, 2020 | $475.60M | +2448.5% |
| FY2019 | Dec 31, 2019 | $18.66M | -45.6% |
| FY2018 | Dec 31, 2018 | $34.29M | +10.0% |
| FY2017 | Dec 31, 2017 | $31.18M | +103.1% |
| FY2016 | Dec 31, 2016 | $15.35M | -57.6% |
| FY2015 | Dec 31, 2015 | $36.25M | +18.2% |
| FY2014 | Dec 31, 2014 | $30.66M | +46.6% |
| FY2013 | Dec 31, 2013 | $20.92M | -5.3% |
| FY2012 | Dec 31, 2012 | $22.08M | +50.3% |
| FY2011 | Dec 31, 2011 | $14.69M | +4182.2% |
| FY2010 | Dec 31, 2010 | $343.00K | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $56.70M | -76.3% |
| Q1 FY2026 | Mar 31, 2026 | $139.51M | -79.1% |
| Q4 FY2025 | Dec 31, 2025 | $147.14M | +66.6% |
| Q3 FY2025 | Sep 30, 2025 | $70.45M | -16.6% |
| Q2 FY2025 | Jun 30, 2025 | $239.24M | -42.4% |
| Q1 FY2025 | Mar 31, 2025 | $666.66M | +610.3% |
| Q4 FY2024 | Dec 31, 2024 | $88.31M | -69.7% |
| Q3 FY2024 | Sep 30, 2024 | $84.51M | -54.8% |
| Q2 FY2024 | Jun 30, 2024 | $415.48M | -2.1% |
| Q1 FY2024 | Mar 31, 2024 | $93.86M | +15.9% |
| Q4 FY2023 | Dec 31, 2023 | $291.34M | -18.5% |
| Q3 FY2023 | Sep 30, 2023 | $186.99M | -74.5% |
| Q2 FY2023 | Jun 30, 2023 | $424.43M | +128.3% |
| Q1 FY2023 | Mar 31, 2023 | $80.95M | -88.5% |
| Q4 FY2022 | Dec 31, 2022 | $357.40M | +60.8% |
| Q3 FY2022 | Sep 30, 2022 | $734.58M | +310.7% |
| Q2 FY2022 | Jun 30, 2022 | $185.93M | -37.6% |
| Q1 FY2022 | Mar 31, 2022 | $703.97M | +57.4% |
| Q4 FY2021 | Dec 31, 2021 | $222.20M | -20.5% |
| Q3 FY2021 | Sep 30, 2021 | $178.84M | +13.9% |
| Q2 FY2021 | Jun 30, 2021 | $298.02M | +738.6% |
| Q1 FY2021 | Mar 31, 2021 | $447.23M | +13143.4% |
| Q4 FY2020 | Dec 31, 2020 | $279.66M | +3072.2% |
| Q3 FY2020 | Sep 30, 2020 | $157.02M | +6163.4% |
| Q2 FY2020 | Jun 30, 2020 | $35.54M | +958.6% |
| Q1 FY2020 | Mar 31, 2020 | $3.38M | -15.2% |
| Q4 FY2019 | Dec 31, 2019 | $8.82M | +43.9% |
| Q3 FY2019 | Sep 30, 2019 | $2.51M | -67.6% |
| Q2 FY2019 | Jun 30, 2019 | $3.36M | -68.8% |
| Q1 FY2019 | Mar 31, 2019 | $3.98M | -58.7% |
| Q4 FY2018 | Dec 31, 2018 | $6.13M | -41.2% |
| Q3 FY2018 | Sep 30, 2018 | $7.74M | -7.4% |
| Q2 FY2018 | Jun 30, 2018 | $10.77M | +60.0% |
| Q1 FY2018 | Mar 31, 2018 | $9.65M | +69.9% |
| Q4 FY2017 | Dec 31, 2017 | $10.41M | +92.9% |
| Q3 FY2017 | Sep 30, 2017 | $8.35M | +158.5% |
| Q2 FY2017 | Jun 30, 2017 | $6.73M | – |
| Q1 FY2017 | Mar 31, 2017 | $5.68M | – |
| Q4 FY2016 | Dec 31, 2016 | $5.40M | – |
| Q3 FY2016 | Sep 30, 2016 | $3.23M | – |
See a number that looks wrong?